Filing Flows › Usana Health Sciences (USNA) › Q4 2025
Usana Health Sciences (USNA) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 16, 2026
Usana Health Sciences (USNA) reported revenue of $226M for the fourth quarter 2025 (Q4 2025), +6% from a year earlier and +6% from the quarter before. Operating margin was 1.7%, net loss $1.6M (0.7% of revenue).
Usana Health Sciences, Q4 2025: revenue $226M (+6% year over year), operating margin 1.7%, net loss $1.6M, operating cash flow −$3.4M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $226M | +6% | +6% |
| Operating profit | $3.8M | +212% | -53% |
| Net earnings | −$1.6M | — | -136% |
| Operating cash flow | −$3.4M | — | -159% |
What changed
Revenue was $226.2M in Q4 2025, up 6% year over year and up 6% from the previous quarter.
Gross margin was 78.2%, down 3.8 points from Q4 2024. Operating profit was $3.8M, a 1.7% margin (down 2.2 points year over year). Operating profit fell $4.4M even though revenue rose $12.6M versus Q4 2024, so costs grew faster than sales. Operating expenses grew 4% against revenue growth of 6%. The quarter ended with a net loss of $1.6M, narrower than the previous quarter's $6.7M loss.
Operating cash flow was −$3.4M. Non-cash charges added back $8.6M of depreciation and amortization and $3.8M of share-based compensation. Working capital and other items used $14.1M. Capital expenditures of $2.8M exceeded it, leaving free cash flow of −$6.2M.
Questions
What was Usana Health Sciences' revenue in the fourth quarter 2025?
Usana Health Sciences (USNA) reported revenue of $226M for the fourth quarter 2025 (Q4 2025), +6% from a year earlier and +6% from the quarter before.
Was Usana Health Sciences profitable in the fourth quarter 2025?
Operating profit was $3.8M (1.7% of revenue) and net loss $1.6M.